A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

Though relapsing-remitting multiple sclerosis, or RRMS, can be managed with many of the approved treatments for MS symptoms, there is still no scientifically proven, FDA-cleared way to predict when or ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the ...

MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics "According to the National Multiple Sclerosis Society, ...

Serum neurofilament light chain (NfL) elevation -- a sign of accelerated neuroaxonal injury -- appeared about 1 year before disability worsening events associated with relapses in multiple sclerosis ...

A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

A previously "hidden" subtype of Multiple Sclerosis (MS)—a condition that affects the brain and spinal cord—has been uncovered. The distinct subtype exhibits "significant cognitive deficits with ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

Multiple sclerosis patients whose blood tests reveal elevated NfL, a biomarker of nerve damage, could see worsening disability one to two years later, according to a new study spearheaded by ...

UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...

Investigators have identified patients who tested positive for the Epstein-Barr Virus 9 years after they were diagnosed with MS, challenging the prevailing notion that the virus precedes MS.